Karyopharm Therapeutics (NASDAQ:KPTI) Now Covered by Analysts at Cantor Fitzgerald

Cantor Fitzgerald began coverage on shares of Karyopharm Therapeutics (NASDAQ:KPTI) in a research report report published on Thursday, Marketbeat Ratings reports. The firm issued an overweight rating on the stock.

Other research analysts also recently issued research reports about the company. Wall Street Zen upgraded Karyopharm Therapeutics from a “strong sell” rating to a “hold” rating in a report on Saturday, November 8th. Robert W. Baird lowered their price objective on Karyopharm Therapeutics from $25.00 to $21.00 and set an “outperform” rating for the company in a research report on Thursday, October 9th. Royal Bank Of Canada dropped their price objective on Karyopharm Therapeutics from $30.00 to $19.00 and set an “outperform” rating for the company in a research note on Tuesday, November 4th. The Goldman Sachs Group set a $12.00 target price on shares of Karyopharm Therapeutics in a research note on Wednesday, December 17th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Karyopharm Therapeutics in a research report on Monday, December 29th. Six investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, Karyopharm Therapeutics has an average rating of “Moderate Buy” and an average target price of $14.83.

Karyopharm Therapeutics Price Performance

Shares of NASDAQ KPTI opened at $6.09 on Thursday. Karyopharm Therapeutics has a one year low of $3.51 and a one year high of $10.38. The firm’s 50 day simple moving average is $6.78 and its two-hundred day simple moving average is $6.10. The stock has a market capitalization of $111.51 million, a P/E ratio of -0.42 and a beta of 0.21.

Karyopharm Therapeutics (NASDAQ:KPTI) last announced its quarterly earnings data on Monday, November 3rd. The company reported ($3.82) earnings per share for the quarter, missing analysts’ consensus estimates of ($3.30) by ($0.52). The firm had revenue of $44.04 million for the quarter, compared to analysts’ expectations of $39.56 million. As a group, equities analysts expect that Karyopharm Therapeutics will post -0.71 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in the stock. Baird Financial Group Inc. purchased a new stake in shares of Karyopharm Therapeutics in the 2nd quarter worth about $45,000. XTX Topco Ltd bought a new stake in Karyopharm Therapeutics during the 2nd quarter valued at approximately $56,000. ADAR1 Capital Management LLC bought a new stake in Karyopharm Therapeutics during the 3rd quarter valued at approximately $164,000. Bridgeway Capital Management LLC purchased a new position in shares of Karyopharm Therapeutics during the 2nd quarter worth approximately $163,000. Finally, Silverback Asset Management LLC raised its position in shares of Karyopharm Therapeutics by 40.0% in the 2nd quarter. Silverback Asset Management LLC now owns 70,000 shares of the company’s stock worth $302,000 after acquiring an additional 20,000 shares in the last quarter. 66.44% of the stock is owned by hedge funds and other institutional investors.

Karyopharm Therapeutics Company Profile

Karyopharm Therapeutics (NASDAQ: KPTI) is a clinical-stage biopharmaceutical company focused on discovering and developing novel first-in-class drugs that target the nuclear export protein XPO1. The company’s lead product, selinexor (marketed as XPOVIO), is an oral selective inhibitor of nuclear export (SINE) compound approved for treatment of multiple myeloma and diffuse large B-cell lymphoma. In addition to selinexor, Karyopharm’s pipeline includes second-generation SINE compounds and combination studies in solid tumors and hematologic malignancies.

Founded in 2008 and headquartered in Newton, Massachusetts, Karyopharm has built a research platform around modulation of nuclear export pathways.